Bristol Myers: FDA approval in schizophrenia

(CercleFinance.com) - Bristol Myers Squibb reports that the FDA has approved its Cobenfy in adults, making it the first new pharmacological approach to treating schizophrenia in decades, with a mechanism of action distinct from current therapies.


The pharmaceutical company points out that this US approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions in schizophrenia symptoms.

The group also announces the launch of Cobenfy Cares, a program designed to support patients prescribed the drug. Patients will be able to sign up for this program at the end of October, subject to product availability.



Copyright (c) 2024 CercleFinance.com. All rights reserved.